Purple Biotech (PPBT) Cash from Financing Activities (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Cash from Financing Activities of -$64000.0 for Q1 2026, down 162.14% year-over-year from $103000.0 in Q1 2025, and down 121.55% quarter-over-quarter from $297000.0 in Q4 2025.
Purple Biotech (PPBT) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Cash from Financing Activities for 10 consecutive years, with -$64000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 162.14% year-over-year to -$64000.0; the TTM figure through Mar 2026 stood at $6.2 million (down 6.7% YoY), while the FY2025 annual figure was $6.3 million, down 6.51% from the prior year.
- Cash from Financing Activities retreated to -$64000.0 in Q1 2026 per PPBT's latest filing, from $297000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $5.6 million in Q3 2025 and bottomed at -$64000.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $1.2 million across 5 years, with a median of $366000.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 4670.79% — and 2026, when it sank 162.14%.
- Purple Biotech's Cash from Financing Activities stood at $89000.0 in 2022, then surged by 4670.79% to $4.2 million in 2023, then dropped by 7.23% to $3.9 million in 2024, then tumbled by 92.46% to $297000.0 in 2025, then tumbled by 121.55% to -$64000.0 in 2026.
- Business Quant data shows PPBT's Cash from Financing Activities at -$64000.0 in Q1 2026, $297000.0 in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64,000.00 |
| Mar 31, 2026 | -64,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Sep 30, 2025 | 5.57 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 366,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 3.94 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 433,000.00 |
| Jun 30, 2024 | 433,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2023 | 4.25 Mn |